Immune booster shows promise against rare cancer
NCT ID NCT02399371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called pembrolizumab in 65 people with malignant mesothelioma, a rare cancer of the lining around the lungs or abdomen. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors or slow the disease, but it is not a cure and ongoing management is needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPHASIC MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New antibody-chemo combo shows promise for mesothelioma
- New drug CT-95 targets tough cancers in early trial
- New drug targets genetic weakness in mesothelioma tumors
- Exercise program for advanced lung cancer patients shows promise